Episode Description
Listen to the episode on a streaming platform by clicking one of the links below:
Humana closed its acquisition of the Florida-based primary care chain MaxHealth, one of the largest such deals since CVS’s purchase of Oak Street Health in 2023.
With MA reimbursement falling behind utilization trends, payviders like Humana and UnitedHealth are leaning further into owned provider assets that might steer downstream volumes away from health systems in competitive markets.
If health systems don’t acquire the care delivery assets that private equity firms are looking to unload, payers might swoop in instead.
The Trump administration is appealing a federal court ruling that struck down a Biden-era regulation expanding what merging companies need to disclose to the FTC.
The appeal signals that the more aggressive antitrust posture that began under the previous administration still retains some bipartisan support.
If the new merger rules are rolled back, a more permissive legal environment for M&A could give growing health systems and financially distressed hospitals more strategic options.
Larger health systems tend to attract more media and antitrust scrutiny, but they also have cheaper access to capital for strategic transformation.
In a 6-3 ruling, the Supreme Court struck down President Trump’s sweeping emergency tariff rates. This week’s featured graphic breaks down the alternative legal authorities that the administration is drawing on to replace them with new tariffs.
CMS unveiled surprisingly low rates for its new ACCESS model, a voluntary alternative payment model for chronic conditions like high blood pressure, diabetes, and depression.
Third-party analysts say the ACCESS rates are significantly lower than the equivalent fee-for-service rates under traditional Medicare, spurring speculation that the new model will only be feasible for startups that replace human clinicians with AI-guided care.
CVS launched a new GLP-1 drug access service that lets employers decide how much they want to subsidize out-of-pocket costs for their employees.
High prescription drug costs remain a top employer concern, and health systems with provider-sponsored commercial plans should consider matching similar features.
Health system-sponsored weight management programs might not be able to compete on cost with virtual-only alternatives pushed by payers.

About Our Host
Anika Rasheed
Anika is a Senior Analyst on the Strategy Catalyst team.